Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-label, Pilot Study of TAK-935 in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder

Trial Profile

A Multicenter, Open-label, Pilot Study of TAK-935 in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs TAK 935 (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Acronyms ARCADE
  • Sponsors Takeda
  • Most Recent Events

    • 04 Jan 2019 According to an Ovid Therapeutics media release, the company plans to complete enrollment in this trial in the second half of 2019.
    • 17 Dec 2018 According to the Ovid Therapeutics media release, the company will amend the protocols for this study to exclude patients being treated with perampanel and, in light of the mode of action of OV935, the duration of treatment will be extended with the potential to observe the extent of the effects of OV935 on seizure reduction over time.
    • 22 Oct 2018 According to an Ovid Therapeutics media release, company has received the 2018 CDKL5 Forum Company Making a Difference Award for initiation of this trial. The first patients have already been enrolled.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top